Phase II trial with melphalan for percutaneous chemosaturation (CS-PHP-Mephalan) in treating unresectable liver metastases of uveal melanoma
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2019
Price : $35 *
At a glance
- Drugs Melphalan (Primary)
- Indications Liver metastases
- Focus Adverse reactions; Therapeutic Use
- 08 Feb 2019 According to a Delcath Systems media release, data from the study has been accepted for oral presentation and as a poster at the European Conference on Interventional Oncology (ECIO) annual meeting 2019.
- 26 Sep 2018 According to a Delcath Systems media release, results from this trial were presented as a poster at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) annual meeting (Sep 2018).
- 26 Sep 2018 Results presented in the Delcath Systems media release.